Literature DB >> 19628038

NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.

Seema Singh1, Muhammad Zahid, Muhammad Saeed, Nilesh W Gaikwad, Jane L Meza, Ercole L Cavalieri, Eleanor G Rogan, Dhrubajyoti Chakravarti.   

Abstract

Estrogens (estrone, E(1); estradiol, E(2)) are oxidized in the breast first to catechols and then to form two ortho-quinones (E(1/2)-3,4-Q) that react with DNA to form depurinating adducts, which lead to mutations associated with breast cancer. NAD(P)H:quinone oxidoreductase 1 (NQO1) reduces these quinones back to catechols, and thus may protect against this mechanism. We examined whether the inheritance of two polymorphic variants of NQO1 (Pro187Ser or Arg139Trp) would result in poor reduction of E(1/2)-3,4-Q in normal human mammary epithelial cells (MCF-10F) and increased depurinating adduct formation. An isogenic set of stably transfected normal human breast epithelial cells (MCF-10F) that express a truncated (135Stop), the wild-type, the 139Trp variant or the 187Ser variant of human NQO1 cDNA was constructed. MCF-10F cells showed a low endogenous NQO1 activity. NQO1 expression was examined by RT-PCR and Western blotting, and catalytic activity of reducing E(2)-3,4-Q to 4-hydroxyE(1/2) and associated changes in the levels of quinone conjugates (4-methoxyE(1/2), 4-OHE(1/2)-2-glutathione, 4-OHE(1/2)-2-Cys and 4-OHE(1/2)-2-N-acetylcysteine) and depurinating DNA adducts (4-OHE(1/2)-1-N3Ade and 4-OHE(1/2)-1-N7Gua) were examined by HPLC with electrochemical detection, as well as by ultra-performance liquid chromatography with tandem mass spectrometry. The polymorphic variants transcribed comparably to the wild-type NQO1, but produced approximately 2-fold lower levels of the protein, suggesting that the variant proteins may become degraded. E(1/2)-3,4-Q toxicity to MCF-10F cells (IC50=24.74 microM) was increased (IC50=3.7 microM) by Ro41-0960 (3 microM), a catechol-O-methyltransferase inhibitor. Cells expressing polymorphic NQO1 treated with E(2)-3,4-Q with or without added Ro41-0960, showed lower ability to reduce the quinone ( approximately 50% lower levels of the free catechols and approximately 3-fold lower levels of methylated catechols) compared to the wild-type enzyme. The increased availability of the quinones in these cells did not result in greater glutathione conjugation. Instead, there was increased (2.5-fold) formation of the depurinating DNA adducts. Addition of Ro41-0960 increased the amounts of free catechols, quinone conjugates and depurinating DNA adducts. NQO1 polymorphic variants (Arg139Trp and Pro187Ser) were poor reducers of estrogen-3,4-quinones, which caused increased formation of estrogen-DNA adduct formation in MCF-10F cells. Therefore, the inheritance of these NQO1 polymorphisms may favor the estrogen genotoxic mechanism of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628038      PMCID: PMC4425209          DOI: 10.1016/j.jsbmb.2009.07.003

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  53 in total

1.  Induction of quinone reductase NQO1 by resveratrol in human K562 cells involves the antioxidant response element ARE and is accompanied by nuclear translocation of transcription factor Nrf2.

Authors:  Tze-chen Hsieh; Xiaohua Lu; Zhirong Wang; Joseph M Wu
Journal:  Med Chem       Date:  2006-05       Impact factor: 2.745

2.  The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity.

Authors:  Muhammad Zahid; Ekta Kohli; Muhammad Saeed; Eleanor Rogan; Ercole Cavalieri
Journal:  Chem Res Toxicol       Date:  2006-01       Impact factor: 3.739

3.  The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C.

Authors:  L T Hu; J Stamberg; S Pan
Journal:  Cancer Res       Date:  1996-11-15       Impact factor: 12.701

Review 4.  Dietary flavonoids: effects on xenobiotic and carcinogen metabolism.

Authors:  Young Jin Moon; Xiaodong Wang; Marilyn E Morris
Journal:  Toxicol In Vitro       Date:  2005-11-11       Impact factor: 3.500

Review 5.  Estrogens as endogenous genotoxic agents--DNA adducts and mutations.

Authors:  E Cavalieri; K Frenkel; J G Liehr; E Rogan; D Roy
Journal:  J Natl Cancer Inst Monogr       Date:  2000

6.  Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis.

Authors:  M M Montano; L J Chaplin; H Deng; S Mesia-Vela; N Gaikwad; M Zahid; E Rogan
Journal:  Oncogene       Date:  2006-12-11       Impact factor: 9.867

7.  Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms.

Authors:  Jay H Fowke; Xiao-Ou Shu; Qi Dai; Fan Jin; Qiuyin Cai; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-08       Impact factor: 4.254

8.  Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones.

Authors:  P A Egner; T W Kensler; T Prestera; P Talalay; A H Libby; H H Joyner; T J Curphey
Journal:  Carcinogenesis       Date:  1994-02       Impact factor: 4.944

9.  Breast cancer: role of polymorphisms in biotransformation enzymes.

Authors:  Jana Sarmanová; Simona Sůsová; Ivan Gut; Marcela Mrhalová; Roman Kodet; Jan Adámek; Zdenek Roth; Pavel Soucek
Journal:  Eur J Hum Genet       Date:  2004-10       Impact factor: 4.246

10.  Urine biomarkers of risk in the molecular etiology of breast cancer.

Authors:  Nilesh W Gaikwad; Li Yang; Sandhya Pruthi; James N Ingle; Nicole Sandhu; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Breast Cancer (Auckl)       Date:  2009-01-06
View more
  9 in total

1.  Redox cycling of catechol estrogens generating apurinic/apyrimidinic sites and 8-oxo-deoxyguanosine via reactive oxygen species differentiates equine and human estrogens.

Authors:  Zhican Wang; Esala R Chandrasena; Yang Yuan; Kuan-wei Peng; Richard B van Breemen; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2010-08-16       Impact factor: 3.739

Review 2.  The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity.

Authors:  Ercole Cavalieri; Eleanor Rogan
Journal:  Mol Aspects Med       Date:  2013-08-30

Review 3.  Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers.

Authors:  Ercole L Cavalieri; Eleanor G Rogan
Journal:  Future Oncol       Date:  2010-01       Impact factor: 3.404

Review 4.  NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.

Authors:  Albena T Dinkova-Kostova; Paul Talalay
Journal:  Arch Biochem Biophys       Date:  2010-03-31       Impact factor: 4.013

Review 5.  Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer.

Authors:  Ercole L Cavalieri; Eleanor G Rogan
Journal:  J Steroid Biochem Mol Biol       Date:  2011-03-21       Impact factor: 4.292

6.  The etiology and prevention of breast cancer.

Authors:  Ercole L Cavalieri; Eleanor G Rogan
Journal:  Drug Discov Today Dis Mech       Date:  2012

7.  Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells.

Authors:  Li Yang; Muhammad Zahid; Yong Liao; Eleanor G Rogan; Ercole L Cavalieri; Nancy E Davidson; James D Yager; Kala Visvanathan; John D Groopman; Thomas W Kensler
Journal:  Carcinogenesis       Date:  2013-07-10       Impact factor: 4.944

8.  Etiology and prevention of prevalent types of cancer.

Authors:  Ercole L Cavalieri; Eleanor G Rogan
Journal:  J Rare Dis Res Treat       Date:  2017-05-02

Review 9.  Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention.

Authors:  Ercole L Cavalieri; Eleanor G Rogan
Journal:  Clin Transl Med       Date:  2016-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.